Description

Yunke Injection is a radiopharmaceutical agent consisting of technetium?99 complexed with methylene diphosphonate, prepared with stannous chloride as reducing agent. The freeze?dried vial is reconstituted prior to use under aseptic conditions. This agent preferentially localizes to bone tissue and sites of active bone remodeling. In both preclinical and clinical studies, Yunke has been used to investigate therapeutic effects in rheumatoid arthritis, osteoporosis, and bone repair, demonstrating inhibition of osteoclast activity and promotion of osteoblast proliferation. Each 5?ml injection contains 5?mg MDP and 0.5?mg SnCl?, with technetium?99 radiolabel. Strictly for laboratory research use only.

Product Specifications

Mechanism of Action & Research Applications

Technetium?99 MDP complex binds to hydroxyapatite crystals in areas of active bone turnover. It accumulates in sites of bone remodeling, such as arthritic joints or healing fractures. In experimental studies, Yunke has demonstrated anti?inflammatory effects in arthritis models by inhibiting osteoclast activity and reducing TNF?? and IL?1? levels, while promoting osteoblast proliferation. It is widely used to model rheumatoid arthritis progression, osteoporosis amelioration, bone healing, and osteoblast differentiation. For preclinical imaging and therapeutic bone-targeting research use only.

Side Effects (For Reference Only in Research Models)

In model systems and clinical analog data, Yunke may produce transient injection-site discomfort, mild systemic symptoms such as fever or headache, and temporary changes in inflammatory markers. Rare radiopharmacological toxicity has been observed at high doses. These effects should inform safety design in preclinical protocols.

Disclaimer

Technetium?99 Methylene Diphosphonate Injection (Yunke) is strictly intended for laboratory research use only. Not for human or veterinary therapeutic or diagnostic use.